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Objectives: The current trend in HTA is its application to local medical facilities 
(called hospital-based HTA or HB-HTA), where HTA methods can foster strategic 
decisions of the hospital management, especially in employing and/or procurement 
of new technology. The essence of HB-HTA utilization is to implement processes that 
allow assessment of the technology considering specific conditions of the hospital. 
Although there are multiple concepts of HTA implementation that can be tailored 
to the particular hospital´s needs, establishing a HTA unit seems the most practical 
in the case of big university hospitals. MethOds: The models must be tailored for 
the Czech healthcare system and specific conditions of the particular hospital. The 
processes accommodated for evaluating, making decisions about and incorporat-
ing technologies are described to supportthe Motol University Hospital’sBoard of 
Directors. The hospital comprises all medical specialties and shows rich technologi-
cal equipment including necessary expertize, providing sufficient internal resources 
for HTA analyses focused on clinical practice. Results: Based on a management 
needs survey, assessment requirements are divided into four categories according 
to their urgency: 1. Urgent, immediate risk of service (device operation) interruption. 
2. Technology requires to be substituted due to impracticability of its recovery. 3. 
Technology requires to be expanded due to existing demand. 4. Incorporation of 
new innovative technology or planned replacement of obsolete technology. For each 
category, a flow chart was designed specifying the assessment process and assess-
ment team composition. The processes have been tested in introducing advanced 
point of care testing methods into the clinical practice in the Motol University 
Hospital. CONCLUSION: The model will be used for establishing working procedures 
of the intended HTA Unit in the Motol University Hospital, and further tested and 
enhanced in line with practical experience. The process is supported by the hospital 
management, who have collaborated on model adjusting.
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bAckgROund: Ireland is one of few countries worldwide to have an explicit cost-
effectiveness threshold. It was agreed in a 2012 agreement between government and 
the pharmaceutical industry. In conjunction with substantial cost-savings on exist-
ing medications the agreement established a threshold of € 45,000/QALY. Prior to this 
there had been an unofficial threshold of € 20,000/QALY. The agreement only applies to 
pharmaceuticals, so there remains no official threshold for non-drug interventions. 
According to the agreement, drugs with cost-effectiveness ratios within the thresh-
old will be granted reimbursement, whereas those exceeding the threshold may 
still be approved following further negotiation. A number of drugs far exceeding 
the threshold have been approved recently. AnAlysis: There are four reasons for 
concern regarding Ireland’s threshold. Firstly, that it only applies to drugs creates 
potential inconsistencies and inefficiencies whereby relatively cost-effective non-
drug interventions are not approved while expensive drugs are. Secondly, as a price 
floor rather than ceiling it offers only a weak constraint on the introduction of cost-
ineffective interventions. Thirdly, it has no apparent empirical basis. Finally, a recent 
threshold estimate based on the cost-effectiveness of services forgone for the UK 
was approximately £13,000/QALY. Assuming Ireland’s threshold should be broadly 
comparable, the current threshold is probably too high. cOnclusiOn: An excessive 
threshold risks causing the Irish health system unintended harm, as newly adopted 
interventions may produce less health than alternative interventions foregone. 
The lack of an empirically-informed threshold means the policy recommendations 
of cost-effectiveness analysis cannot be considered fully evidence-based rational 
rationing. Finally, it also means that the current threshold does not accord with 
recent legislation on the pricing of medical goods, which defines cost-effectiveness 
in terms of the opportunity cost of other services foregone. Policy makers should 
consider these issues when choosing what threshold to apply once the current 
industry agreement expires at the end of 2015.
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Objectives: Hernia repair is one of the most commonly performed surgical 
procedures. Hernia societies encourage surgical decisions based on up-to-date 
evidence-based guidelines rather than surgical intuition. The objective was to 
identify whether surgical guidelines and protocols for hernia repair can reduce 
costs and improve patient outcomes, and whether they are followed. MethOds: 
Comprehensive literature search to identify publications on hernia repair guide-
lines and summarise their impact on cost and patient outcomes. Results: A 
Dutch study that compared inguinal hernia repair outcomes before and after evi-
dence-based guidelines were introduced showed a significant reduction in hernia 
recurrence when guidelines were followed. A Spanish study of emergency ventral 
hernia repairs found that the proportion of patients treated after introduction of 
a protocol was significantly lower for mortality following bowel resection and the 
incidence of severe complications was reduced (excluding femoral hernia) versus 
pre-protocol. Introduction of a protocol for inguinal hernia repair in a UK general 
hospital improved patient outcomes to a level comparable with a specialist hernia 
centre. The authors also reported potentially large cost savings by increasing the 
proportion of ambulatory patients and those that received local anaesthesia. The 
Royal College of Surgeons noted that ambulatory operations are recommended 
for 80% of groin hernia repairs but found that only 67% were ambulatory, rang-
ing from 32–100% across UK healthcare providers. Another UK study looked at the 
uptake of NICE guidelines for several procedures, including laparoscopic repair of 
inguinal hernia, and reported that although Hospital Episode Statistics suggested 
96% compliance, a detailed audit of healthcare trusts showed only 65% compli-
this study was to analyze how the KA model could be institutionalized within the 
HTA framework. MethOds: We conducted a systematic search on “KA” theoretical 
approaches and empirical evidence. Based on a comparative analysis of relevant 
articles, and over a series of discussion meetings with different stakeholders, we 
generated an adjusted KA model fitting the purposes of HTA. Then, we identified the 
key institutional questions that would be relevant for the institutionalization of the 
adjusted KA model in the context of HTA. Results: The evidence on the KA model 
focuses on solving real problems, the use of evidence from different sources, and the 
need of including preferences of evidence users in real life, all elements included in 
the adjusted version. The institutionalization of KA within the HTA framework is 
challenged by, at least, the following questions: (i) which is the right way of choosing 
representative evidence users (e.g. healthcare team), stakeholders (health policy 
makers), and those affected by evidence use (patients); (ii) how to monitor the adap-
tation of guidelines to local contexts, (iii) which are the sets of rules that model the 
stakeholder´s behaviour, (iv) and which are the implied outcomes that are expected 
from these rules. cOnclusiOns: The KA model adds important elements to HTA, 
which can be useful for the institutionalization processes in many countries of the 
world. This piece of research identified the main components/questions that need 
to be addressed to undertake this institutional process.
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bAckgROund: Mature products (MPs - marketed for 10 years or more) are widely 
used off label (from 15 to 35% according to studies) despite little evidence on benefit 
risk ratio. This exposes patients to risks or lack of efficacy and healthcare providers 
to liability. However manufacturers are rarely investing in R&D development for MPs. 
Indeed MPs face price cuts in Europe, whether due to generic competition, price 
negotiations or inclusion in reference price groups. Moreover new indications, even 
if demonstrating a higher value of the drug, often lead to price reductions in Europe 
due to a combination of price/volume agreements and external reference pricing. 
Products are included in reference price groups even for a new indication. While refer-
ence price groups only include off-patent drugs in France and Italy, these groups may 
include patented drugs in Spain (if older than 10 years) and Germany.There are sig-
nificant disincentives for manufacturers to invest in R&D for MPs, preferring instead 
to develop new molecular entities rather than unlocking the full therapeutic potential 
of MPs. This is especially the case for small populations (rare and ultra-rare diseases) 
where there is high unmet medical need and MPs could offer cost-effective solutions 
with known safety profiles. discussiOn: The development of new indications for 
MPs can be a win-win solution for patients and payers. It offers an alternative to off 
label or lengthy and expensive development of new therapies, as well as more equity 
in patients’ access to treatment. As safety accounts for approximately 30% of drug 
failures in clinical trials, mature products can also offer a quicker and less expensive 
access to therapy, especially in areas of high unmet need. cOnclusiOn: Incentives 
for orphan drugs or pediatric indications have proven to be effective in promoting 
R&D. New incentives should be developed to promote R&D in MPs.
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Developing countries moving to universal coverage seek to increase medicine 
access. They face the problem of determining which medicines to reimburse and 
how to set price and access for them. Medicine price and access are set by many 
organisations in developing countries - ministry of health, hospitals, national/
regional payers and procurement bodies - with limited or no data on prices and 
utilisation. This leads to a fragmented system with widely varying price and access 
levels within the same country. Ad hoc solutions such as median pricing, inter-
national price referencing (IRP), HTA or arbitrary price cuts, with no overarching 
framework or logic, exacerbate the problems leading to supply shortages, poor 
quality, irrational use and continuing large differences in price and access. There is 
no consistent mechanism for setting price and access for innovative medicines. In 
the few countries performing cost-effectiveness assessments, these medicines are 
almost never found to be cost effective at local thresholds. In this paper, we lay out 
a structured Pricing and Patient Access (PPA) framework that empowers countries 
with effective approaches and tools to price medicines. These include competi-
tive pricing for generics and setting price/access based on benefit assessment 
for patented medicines. Specific tools such as IRP, therapeutic referencing and 
price-volume/risk-share negotiations and managed entry agreements can then be 
used within this overall framework to improve access to priority medicines. While 
many of these tools exist in developed countries, we develop specific adaptations 
for developing countries. Further, building of such systems faces obstacles such 
as a cognitive disconnect between what stakeholders think they know and what 
they really know about PPA, institutional fragmentation, stakeholder buy-in and 
limited local capabilities (number of staff, skills, IT systems to track price and 
utilisation). To address these we also lay out a pathway to reform that addresses 
each of these issues.
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by the health insurer. The IT systems of health insurers and hospitals need to 
be adapted. RecOMMendAtiOns: A working group led by the pharma industry 
association and major health insurers (including pharma companies, hospital 
administration and oncologists) will set up pilots with oncology clinics to test 
the feasibility of implementing an indication code and work on sustainable pric-
ing models for TCRs. cOnclusiOn: Goal would be a standardised processing of 
the remuneration for TCRs based on indication code and the underlying pricing 
model. For scale up the FOPH would have to mandate the adoption of the approach 
at national level.
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bAckgROund: The prospects of Brexit (UK exit from the EU) and Grexit (Greek exit 
from the Eurozone) have significant implications for the European pharmaceutical 
industry. In recent years, exiting the EU has been actively debated in the UK. While 
not a member of the Eurozone, the UK is a key member of the EU trade bloc. The 
UK government plans to hold a referendum by 2017; recent polls indicate 35-45% 
of Brits support withdrawal. In contrast, Greek withdrawal from the Eurozone may 
occur if the government is unable to reach an agreement with their creditors on 
the repayment of Greek sovereign debt. Failure to meet a € 1.6 billion payment to 
the IMF at the end of June 2015 may result in Eurozone withdrawal. iMpAct: As 
an EU member state, the UK forms a significant component of international refer-
ence pricing baskets for many other states; an arrangement which may or may not 
continue in the event of Brexit. Despite the independence of the British pound, 
Brexit may lead to further regional price disparity due to currency fluctuations. 
Both Brexit and Grexit are likely to have a significant impact on parallel trade 
amongst EU member states (parallel imports represent ~20% of UK drug sales, 
whereas exports for parallel trade account for ~12% of the Greek pharmaceutical 
market). Additionally, Grexit may impact the purchasing power of Greeks and their 
government’s ability to fund healthcare access to medicines. MethOdOlOgy: 
Navigant conducted qualitative interviews with payers and budget holders to 
understand expectations of the impact of Grexit and Brexit, anticipated strate-
gies in response to these withdrawals, the level of disruption to pharmaceutical 
supply and potential drug shortages. cOnclusiOns: Additional monitoring and 
appropriate planning is essential. The high level of uncertainty requires further 
consideration; Brexit and Grexit present significant implications to a broad array 
of stakeholders.
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bAckgROund: There are differences across the world in the definitions used to 
classify an orphan drug (OD), especially with respect to the prevalence of the dis-
ease justifying the orphan status and, the estimation of the population affected 
by the disease. Objective: To identify the number of medicines which have been 
granted orphan designation in the United States (US) and European Union (EU), 
and analyse the approval trends over a ten-year time horizon. MethOds: All ODs 
authorised by the European Medicines Agency (EMA) and approved by the US Food 
and Drug Administration (FDA) were identified on the 1st May 2015 by downloading 
the databases available from their respective websites. Duplicates were removed 
in both cases using non-proprietary name and the lists were filtered to capture 
the period from 01/01/2005 to 31/12/2014. Results: The databases downloaded 
from the EMA and FDA had n= 93 and n= 237 results respectively. Removing the 
duplicates reduced these to n= 91 and n= 197 respectively. Filtering the list to select 
ODs authorised between the 01/01/2005 and 31/12/2014 gave final values of n= 74 and 
n= 189 respectively. ANALYSIS: The number of ODs approved significantly increased 
in numbers between the years 2005 and 2014 in the US and in the EU. In 2014 the 
EMA authorised 5 times as many ODs as they did in 2005 (15 vs 3 respectively) and 
a similar trend was observed in the US, where in 2014 the FDA authorised twice 
as many ODs as they did in 2005 (30 vs 14). cOnclusiOns: In 2005 the number of 
ODs authorised was significantly lower than that of 2014 and the designation of 
orphan diseases and approval of ODs was rare. 10 years on and gaining OD status 
for a sub population based rare disease appears from the outside to have become 
an objective for a number of pharmaceutical companies.
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Objectives: To evaluate the potential for RSA implementation in Bulgaria and to 
outline the necessary legislative changes. MethOds: A literature review of the 
existing in EU RSA schemes and review of the local legislation were done to identify 
the laws and regulations intended for changes. Results: Bulgarian government has 
recently carried out major changes within the Health Insurance Act. The adopted 
texts introduced a “no discount - no reimbursement” rule, creation of HTA body 
and formal HTA assessment for all new and existing medicines with re-assessment 
every three years. The new HTA body is expected to adopt a threshold for cost-
effectiveness. Companies will be allowed to provide discounts for new medicines 
before reimbursement decision hence to influence the cost-effectiveness. The new 
measures are focusing mainly on the prices of the medicines, as were the old one 
(voluntary discounts to NHIF). The National Health Insurance Fund (NHIF) should 
consider other options which will give them opportunity for broader based negotia-
tions with the MAHs. As such option could be considered the implementation of RSA 
ance. cOnclusiOns: The following of protocols and guidelines for hernia repair 
has been shown to improve patient outcomes and reduce costs but the degree of 
uptake is variable. This suggests that there is scope for greater protocol/guideline 
adherence and resultant cost savings in hernia repair
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Objective: France has large markets for pharmaceuticals in Algeria; moreover, 
Algerian authorities look to France for reference pricing. In recent times, the HAS 
is increasingly the influential health technology assessment (HTA) agency. French 
speaking countries are referencing and following the HAS decisions. The main objec-
tive of this study is to assess the HAS influence in North Africa region (Morocco, 
Algeria, Tunisia) in their reimbursement decisions. MethOd: To have a comprehen-
sive study, a sample of medicines was determined, and these drugs had obtained 
positive recommendation by HAS during a period from January 2013 to December 
2013.Then, the recommendation from HAS were matched with the North African 
decision. Result: Total drugs approved for their first inscription were 258, where 
one drug obtained ASMR II, 12 obtained ASMR III, 13 noted ASMR IV and 232 ASMR 
V. When we have analyzed the common reimbursement decision taken according 
the level of ASMR We have observed that Morocco reimburse the drugs product with 
ASMR III and ASMR IV. However Algeria and Tunisia reimburse less the medicines 
with ASMR IV and V cOnclusiOn: This study demonstrates that the discordance 
between countries reimbursement decisions. In most cases it may reflect the dif-
ferences in the decision making process and in their constraint budget: Payers in 
Morocco are following HAS recommendation whereas Tunisia and Algeria there are 
following less HAS decisions.
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bAckgROund infORMAtiOn: In 2014, Romania adopted a new legislation requiring 
Health_Technology_Assessment (HTA) as mandatory step in the drug reimbursement 
listing. The HTA System is a score-card, the drug/ a certain indication can be 
unconditional (80 – 145 points), or conditional approved (60-79 points). Conditional 
approved indications are reimbursed only if they are included in a cost-volume/cost-
volume-result contract (CV/CVR) with the National Payer,- requiring the tracking of 
drug utilisation data on indication. This could lead to differentiated pricing, depend-
ing on the benefit the product provides in different indications (Multiple Indication 
Pricing-MIP). One single unit price could be not relevant for all indications (e.g in 
oncology), especially when the same drug has both unconditional and conditional 
reimbursement. AppROAch: Under MIP, drug utilisation would be tracked; the price 
of medicine per indication would be defined according to the benefit of the drug 
in that indication. Two approaches could be used: leverage existing national data 
collection by the National Payer, additionally collecting data like indication, treat-
ment status, result, etc. by a separate module in the Hospital Information System 
or use e-health/electronic patient records. Implications: Required minimum data 
fields, data format and attributes must be defined. Data must be complete, con-
sistent, available, allowing for validity checks. Marketing Authorization Holder 
(MAH) must receive reports containing information (anonymised and aggregated) 
on drug utilisation. To be defined: timing between data capturing and data avail-
ability, timing for paybacks, absorption of costs for data generation and capturing, 
error handling. RecOMMendAtiOns: Conduct pilot with a representative oncology 
clinic, set a methodology for collection, validation and use of data, generate reports, 
demonstrate the utility in managing CV/CVR. Scale up the project at national level 
through the National_Health_Insurance_House. cOnclusiOn: Developing a system 
to identify drug utilisation on indication, could support implementing conditional 
reimbursement schemes by the Payer and increase patient access to drugs.
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bAckgROund infORMAtiOn: Targeted Combination Regimes (TCRs) could sig-
nificantly improve outcomes for cancer patients in future as drugs with different 
and complementary mechanisms of action often act synergistically to improve 
treatment results. Despite the potential benefits of TCRs there are also chal-
lenges associated with them. Several combination therapies involve more than 
one Marketing Authorization Holder, adding the cost of two medicines on top of 
each other combined with potentially longer therapy duration could make the 
funding of such TCRs unsustainable. The Federal_Office_of_Public_Health (FOPH) 
currently commands price negotiation at brand level, resulting in a single price per 
product, however in the future a more flexible pricing system might be required 
in order to enable fast patient access while making sure TCRs remain effective, 
expedient and economical. AppROAch: One approach could be the introduction 
of an indication code on the billing process. The indication code could help health 
insurance companies to identify TCRs and allow a fast reimbursement through a 
simple and standardised process. Flexible pricing models would make sure that 
TCRs remain economical. implications: Patients would have to agree that infor-
mation on their condition (e.g. indication, molecular profile, therapy) would be 
captured on the billing process. The indication code would have to be encrypted 
